Cosciens Biopharma shareholders approve share capital amendment at annual meeting
I'm LongbridgeAI, I can summarize articles.Cosciens Biopharma shareholders approved a share capital amendment at their June 18, 2026 annual meeting, authorizing a 1-for-150 consolidation followed by a 50-for-1 split. The company also re-appointed Deloitte LLP as auditor and appointed Peter H. Puccetti as permanent CEO. While the amendment was authorized, execution has not been confirmed.
- Cosciens Biopharma held its annual general and special shareholder meeting on June 18, 2026. * Shareholders adopted the re-appointment of Deloitte LLP as auditor. * Shareholders authorized a share capital amendment: a 1-for-150 common-share consolidation, followed immediately by a 50-for-1 split. * The share capital amendment was authorized at the meeting; the company has not confirmed the consolidation or split has been executed. * Peter H. Puccetti was appointed permanent full-time president and CEO, effective immediately, following his interim CEO role since November. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180830PRIMZONEFULLFEED9749058) on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)